Epinephrine is under clinical development by Klaria Pharma Holding and currently in Phase I for Anaphylaxis. According to GlobalData, Phase I drugs for Anaphylaxis have an 88% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Epinephrine’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Epinephrine overview

Epinephrine (KL-01401) is under development for the treatment of anaphylaxis. The drug candidate is administered as oromucosal films. It acts by targeting alpha (1, 2) and beta (1,2) adrenergic receptors.

Klaria Pharma Holding overview

Klaria Pharma Holding (Klaria Pharma) is a pharmaceutical company. It develops fast acting medicinal products for the treatment of cannabinoids, migraine, opioid overdose and cancer related pain. The company’s patented drug delivery platform features is an alginate based polymer film which facilitates a quick transmucosal absorption and distribution of the marketed drugs or clinical substances directly to the bloodstream. Klaria Pharma also offers other stable supply forms including nasal sprays and orally dissolvable tablets. It offers its products to customers worldwide through distributors. Klaria Pharma is headquartered in Uppsala, Sweden.

For a complete picture of Epinephrine’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.